A good start to the year despite COVID-19

UPPSALA, Sweden, April 28, 2020 /PRNewswire/ —

Q1 2020 highlights         

Total net revenues of SEK 175.0 m (174.3), up 0.4 percent            

EBITDA of SEK 39.1 m (12.0), up 225.8 percent            

Net earnings of SEK 82.6 m (14.1), up 485.8 percent           

US Pharma (Zubsolv® US) net revenues of SEK 163.9 m (161.7), up 1.3 percent in SEK and -4.0 percent in local currency. HQ & Pipeline net revenues of SEK 11.1 m (12.6).           

US Pharma (Zubsolv US) EBIT of SEK 75.9 m (68.2), up 11.2 percent, Digital Therapeutics EBIT of SEK -12.0 m (-) and HQ & Pipeline EBIT of SEK -29.9 m (-67.1)           

Cash flow from operating activities of SEK 48.1 m (50.9), building a cash balance of SEK 861.4 m (647.4)           

OX338 showed promising results